What this is
- How it works
- How it works isn't classified yet
- Tested for
- Fecal Incontinence
- Main trialPhase 1
- “This is first-in-human prospective Phase I study of the immediate and long-term safety of an implanted internal anal sphincter (IAS) bioengineered from autologous cells to treat subjects with severe passive FI who have failed standard treatments.”In the company’s words, NCT05616208 on ClinicalTrials.gov
Other drugs for Fecal Incontinence
- IltamiocelCook MyoSite · Phase 3
- ASMDCInnovacell GmbH · Phase 3
Coming up1
- Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Jul 2027 | Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026